Drug intelligence / Profile preview

ESG411

Development stage: Preclinical
Lead developer: Shanghai Escugen Biotechnology
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ESG411 is an investigational bispecific antibody-drug conjugate (ADC) being developed by Shanghai Escugen Biotechnology. It is designed to simultaneously target two distinct, currently undisclosed tumor-associated antigens to deliver a cytotoxic payload directly to cancer cells. This bispecific approach is intended to enhance tumor specificity, increase internalization rates, and potentially overcome resistance mechanisms compared to traditional monospecific ADCs. The primary therapeutic focus for ESG411 is the treatment of non-small cell lung cancer (NSCLC).

Targets

TACSTD2 (Tumor-associated calcium signal transducer 2)

Beyond the preview

Go deeper on ESG411.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ESG411.

Explore the full profile